Anna Mackin, MD
Retina Specialist · Roanoke, VANPI 1245619105
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by AbbVie at 28.9% of the total. Reporting peaked in 2024 at $11,027 and has fallen 84.5% since, to $1,710 in 2025. Among retina specialist clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $135.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Alimera Sciences, Inc.$4K
- Ocular Therapeutix, Inc.$4K
- Glaukos Corporation$3K
- Regeneron$3K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $4K from 15 others
Across 23 payments — averaging $5895.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$134K
- Regeneron$2K
What the payments were for
- Consulting fees$10,11739%
- Speaking & faculty fees$6,01923%
- Travel & lodging$2,69410%
- Food & beverage$7,04127%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 51 | $7,472 |
| Alimera Sciences, Inc. | 23 | $4,091 |
| Ocular Therapeutix, Inc. | 9 | $4,089 |
| Glaukos Corporation | 2 | $2,679 |
| Regeneron | 3 | $2,660 |
| Regeneron Healthcare Solutions, Inc. | 31 | $1,354 |
| Alcon | 4 | $1,290 |
| Astellas Pharma US Inc | 11 | $416 |
| Novartis | 3 | $348 |
| Bausch & Lomb Americas Inc. | 12 | $288 |
| Genentech, Inc. | 3 | $259 |
| Eyepoint US, Inc. | 6 | $245 |
| Genentech USA, Inc. | 11 | $196 |
| Apellis Pharmaceuticals, Inc. | 7 | $162 |
| Biogen | 6 | $111 |
| ANI Pharmaceuticals, Inc. | 3 | $78 |
| Coherus Oncology, Inc. | 2 | $44 |
| GSK | 1 | $28 |
| Sandoz | 1 | $27 |
| Harrow Eye, LLC | 1 | $18 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$6,598
- Iluvien$3,590
- EYLEA HD$2,708
- iStent Trabecular Micro-Bypass System Model iS3$2,500
- YUTIQ$1,629
- EYLEA$588
- BEOVU$244
- Izervay$229
- KXL System$179
- iStent infinite Trabecular Micro-Bypass System Model iS3$179
- NGENUITY$136
- VABYSMO$126
How this compares
$25,870 in reported general payments places this provider in the 90th percentile of 41 retina specialist providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 201 | $6,010 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $2,828 |
| Difluprednate | 23 | $1,934 |
| Ketorolac Tromethamine | 85 | $1,629 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 69 | $1,402 |
| ErythromycinErythromycin Base | 104 | $1,037 |
| MoxifloxacinMoxifloxacin Hcl | 34 | $849 |
| Dorzolamide Hcl | 47 | $630 |
| Latanoprost | 38 | $502 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 35 | $410 |
| Brimonidine Tartrate | 60 | $357 |
| Ofloxacin | 36 | $356 |
| Timolol Maleate | 40 | $334 |
| Atropine Sulfate | 12 | $158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan | $7,472 | $2,82813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 41 retina specialist providers in Virginia.
Other retina specialist in Roanoke
- Timothy ByrnesRoanoke$7K
- Jordana FeinManassas$412K
- Joaquin TosiVirginia Beach$48K
- Mohit NandaCharlottesville$31K
- Muge KesenMc Lean$30K
- Jon AdlebergChesapeake$21K
- Dal ChunVienna$12K
- Kori ElkinsPortsmouth$9K
- Jiwei ShengFairfax$8K
- Alexander MelamudFairfax$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.